EDMONTON, Alberta, Oct. 27, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ/CSE: SNDL) ("SNDL" or the "Company") reported its financial and operational results for the third quarter ended September 30, 2026. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated.
SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com.
The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Tuesday, October 27, 2026. The conference call details can be found below.
MANAGEMENT HIGHLIGHTS
-- Net revenue for the third quarter of 2026 was $238.0 million,
representing a -2.5% decrease compared with the same period of the prior
year. Cannabis Retail revenue increased by 0.7%, while Liquor Retail and
Cannabis Operations revenue declined by -3.3% and -27.7%, respectively.
-- Gross profit of $57.9 million for the third quarter of 2026 represents a
decline of $(6.3) million, or -9.8%, compared with the same period of the
prior year.
-- Gross margin (1) was 24.3% in the third quarter of 2026, a decrease of
2.0 percentage points compared with the same period of the prior year,
primarily reflecting weak performance of Cannabis Operations. Both retail
segments delivered strong margin expansion and reached new quarterly
records.
-- Operating loss was $(48.3) million for the third quarter of 2026,
reflecting a $52 million non-cash goodwill impairment charge related to
the Cannabis Operations segment.
-- Adj. operating income (1), which excludes impairment charges and
restructuring costs, returned to positive territory at $5.2 million, an
improvement of $14.8 million compared with the same period of the prior
year.
-- Cash flow was $(50.7) million, reflecting $60.8 million of strategic
investments in the U.S. and $10.0 million of additional share repurchases,
consistent with our capital allocation priorities.
-- Free cash flow (1) reached a new quarterly record of $20.0 million in the
third quarter of 2026, an increase of $3.3 million, or 19.5%, compared
with the same period of the prior year, including a $10.6 million benefit
associated with the initial unwinding of the Company's captive insurance
arrangement.
"Our third quarter results demonstrate improvement in SNDL's underlying financial performance, including positive adjusted operating income and record quarterly free cash flow generation," said Zach George, Chief Executive Officer of SNDL. "Cannabis Retail delivered record quarterly revenue and gross margin, Liquor Retail also reached a new record quarterly gross margin, and our Investments segment benefited from improved results from equity-accounted investees."
"Cannabis Operations remained below expectations and recorded a non-cash impairment. While the quarter was impacted by inventory issues arising from the first half, we are taking decisive action to simplify the portfolio, reduce costs and concentrate resources on product categories where SNDL's manufacturing capabilities, distribution reach and retail insights can support sustainable returns. The benefits of the actions taken during the quarter are expected to begin contributing to results in the fourth quarter. In addition to these immediate actions, the Company is initiating a strategic review of the Cannabis Operations segment to assess opportunities to improve its financial performance. The review will consider a range of strategic and operational alternatives, from potential asset divestitures to larger productivity initiatives."
"The completion of the restructuring of Surterra Holdings, Inc. ("Parallel") in July of this year, which reduced its debt burden by approximately US$842 million, and the subsequent rights offering, which increased our indirect equity ownership from approximately 67% to 92%, represent important steps in resetting Parallel's capital structure and providing liquidity to support inventory, product availability and critical supply-chain infrastructure. SNDL-funded investments by SunStream Bancorp Inc. ("SunStream") in a new cultivation facility in Gainesville, Florida, are expected to enhance Parallel's cost structure. We are excited by the opportunity presented by our investment in Parallel and are actively exploring the feasibility of transitioning our indirect economic exposure to direct ownership and consolidation of qualifying U.S. medical cannabis operations, subject to applicable legal, regulatory, accounting and Nasdaq requirements."
"We are encouraged by the progress made toward resolving the regulatory matters involving the Alcohol and Gaming Commission of Ontario ("AGCO"), which we expect will provide greater clarity for the Ontario franchise retail operations and future development opportunities, as further detailed later in this document and in the Q3 2026 Earnings Call presentation."
"Across SNDL, our priorities remain disciplined capital allocation, improved operating performance and long-term value creation for shareholders. We have demonstrated that commitment through significant share repurchases, and we intend to remain aggressive when we believe the opportunity to acquire our shares represents an attractive use of capital. The recently announced potential $50 million substantial issuer bid ("SIB") is a further step toward accelerating capital returns and reducing our outstanding share count," concluded Zach George.
TOTAL COMPANY HIGHLIGHTS
Three months ended September 30 Nine months ended September 30
($000s) 2026 2025 % Change 2026 2025 % Change
------------ -------- ------- -------- -------- ------- --------
IFRS
Financial
Measures
------------
Net revenue 237,994 244,219 -2.5% 669,666 693,902 -3.5%
Gross profit 57,886 64,177 -9.8% 167,047 188,419 -11.3%
Operating
income
(loss) (48,317) (11,050) -337.3% (65,272) (18,100) -260.6%
Change in
cash and
cash
equivalents (50,729) 32,357 -256.8% (107,622) 22,222 -584.3%
Non-IFRS
Financial
Measures
(1)
------------
Gross margin 24.3% 26.3% -2.0 pp 24.9% 27.2% -2.2 pp
Adjusted
operating
income
(loss) 5,249 (9,512) 155.2% (10,675) (12,713) 16.0%
Free cash
flow 19,954 16,692 19.5% 5,692 7,733 -26.4%
(1) Gross Margin is a supplementary financial measure calculated by dividing Gross Profit by Net Revenue. Adjusted operating income (loss) and Free Cash Flow are specified financial measures that do not have standardized meanings under IFRS and therefore may not be comparable to similar measures reported by other companies. See "Non-IFRS Measures" section below for further information.
BUSINESS SEGMENT HIGHLIGHTS
SNDL operates and reports its business through four segments: Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments. Additionally, a consolidated total for Cannabis is presented, encompassing the combined results of the two Cannabis segments, along with the revenue elimination associated with the Cannabis Operations sales to the provincial boards that are expected to be subsequently repurchased by the Company's licensed retail subsidiaries for resale. Corporate and shared service expenses are reported as "Corporate".
Three months ended September Nine months ended September
30 30
($000s) 2026 2025(2) % Change 2026 2025(2) % Change
Net Revenue
----------------
Cannabis
Retail 85,605 85,021 0.7% 246,154 246,960 -0.3%
Cannabis
Operations 27,040 37,389 -27.7% 88,704 107,544 -17.5%
Intersegment
Eliminations (9,425) (17,579) 46.4% (38,757) (51,391) 24.6%
Total Cannabis 103,220 104,831 -1.5% 296,101 303,113 -2.3%
Liquor Retail 134,774 139,388 -3.3% 373,565 390,789 -4.4%
Investments -- -- 0.0% -- -- 0.0%
Total 237,994 244,219 -2.5% 669,666 693,902 -3.5%
Operating Income
----------------
Cannabis
Retail 5,244 5,047 3.9% 9,328 10,557 -11.6%
Cannabis
Operations (64,693) (10,882) -494.5% (80,836) (20,186) -300.5%
Total Cannabis (59,449) (5,835) -918.8% (71,508) (9,629) -642.6%
Liquor Retail 6,035 6,591 -8.4% 5,899 10,884 -45.8%
Investments 7,861 1,543 409.5% 8,340 1,775 369.9%
Corporate (2,764) (13,349) 79.3% (8,003) (21,130) 62.1%
Total (48,317) (11,050) -337.3% (65,272) (18,100) -260.6%
Adjusted
Operating
Income
----------------
Cannabis
Retail 5,284 5,047 4.7% 9,403 10,557 -10.9%
Cannabis
Operations (11,391) (10,220) -11.5% (27,303) (16,258) -67.9%
Total Cannabis (6,107) (5,173) -18.1% (17,900) (5,701) -214.0%
Liquor Retail 6,037 6,591 -8.4% 6,126 10,884 -43.7%
Investments 7,861 1,543 409.5% 8,340 1,775 369.9%
Corporate (2,542) (12,473) 79.6% (7,241) (19,671) 63.2%
Total 5,249 (9,512) 155.2% (10,675) (12,713) 16.0%
(2) In 2026, the Company began allocating applicable direct and indirect overhead costs from the corporate segment to each individual operating segment all categorized within general and administrative expenses. The Company has recast the comparative period to illustrate the impact of these allocations had they been done during the prior period, as documented in the condensed interim Financial Statements.
Liquor Retail
SNDL is Canada's largest private-sector liquor retailer, operating as of October 26, 2026 in 165 locations, predominantly in Alberta, under its three retail banners: "Wine and Beyond" (16), "Liquor Depot" (19), and "Ace Liquor" (130).
Three months ended September 30 Nine months ended September 30
($000s) 2026 2025 % Change 2026 2025 % Change
---------- -------- ------- -------- ------- ------- --------
Net revenue 134,774 139,388 -3.3% 373,565 390,789 -4.4%
Gross
profit 36,390 36,704 -0.9% 96,828 100,993 -4.1%
Gross
margin 27.0% 26.3% 0.7 pp 25.9% 25.8% 0.1 pp
Operating
income 6,035 6,591 -8.4% 5,899 10,884 -45.8%
Adjusted
operating
income 6,037 6,591 -8.4% 6,126 10,884 -43.7%
-- Net revenue for Liquor Retail continued to decline year over year in the
third quarter of 2026, although at a slightly better rate than in
previous quarters. Persistent softness in market demand continued to
affect same-store sales(3), which decreased by -6.0% compared with the
same period in the prior year.
-- Operating income declined year over year, driven by lower revenue,
increased promotional support, and higher SG&A expenses associated with
the recent Wine & Beyond store openings, partly offset by strong gross
margin expansion, which reached a new quarterly record.
(3) Same-store sales is a specified financial measure that does not have standardized meanings under IFRS and therefore may not be comparable to similar measures used by other companies. See "Non-IFRS Measures" section below for further information.
Cannabis Retail
SNDL is one of Canada's largest private-sector cannabis retailers, operating as of October 26, 2026 in 193 locations under two retail banners: "Value Buds" (133) and "Spiritleaf" (60, of which 4 are corporate stores and 56 are franchise stores). The Company's Cannabis Retail strategy is based on several pillars, including high-quality store locations, a broad product assortment and differentiated customer experiences. Using data and insights from a large volume of monthly transactions enables SNDL to leverage technology and analytics to inform and improve its retail strategy.
Three months ended September 30 Nine months ended September 30
($000s) 2026 2025 % Change 2026 2025 % Change
---------- ------- ------ -------- ------- ------- --------
Net revenue 85,605 85,021 0.7% 246,154 246,960 -0.3%
Gross
profit 23,118 22,465 2.9% 65,472 63,974 2.3%
Gross
margin 27.0% 26.4% 0.6 pp 26.6% 25.9% 0.7 pp
Operating
income 5,244 5,047 3.9% 9,328 10,557 -11.6%
Adjusted
operating
income 5,284 5,047 4.7% 9,403 10,557 -10.9%
-- Net revenue for Cannabis Retail returned to growth in the third quarter
compared with the same period of the prior year, consistent with the
previously anticipated inflection point, and reached a new quarterly
record. Market contraction in our largest provinces (ON, AB) contributed
to a -3.8% decline in same-store sales. This decline was partially offset
by incremental revenue from new stores and Value Buds store conversions.
-- Operating income increased compared with the same period of the prior
year, primarily driven by gross margin expansion, which reached a new
quarterly record, despite lapping a larger impairment reversal recorded
in the third quarter of 2025.
-- Subject to completion of definitive documentation and payment of a
$200,000 monetary penalty, the anticipated resolution of the regulatory
matters involving the AGCO is expected to allow the Value Buds franchise
network to resume growth in Ontario following a pause of more than a year
during the regulatory review. While the contemplated structure is
expected to result in the deconsolidation of the Ontario retail
operations from SNDL's financial statements, we expect the overall
commercial arrangements to substantially preserve SNDL's net economics
associated with these franchise locations, without retaining control over
the retail operations in the province.
Cannabis Operations
SNDL has a diverse brand portfolio from value to premium, emphasizing premium inhalable formats and a full suite of 2.0 products. With enhanced procurement capabilities and plans to continue evolving toward a cost-effective cultivation and manufacturing operation, the Cannabis Operations segment is a key enabler of SNDL's vertical integration strategy.
Three months ended September 30 Nine months ended September 30
($000s) 2026 2025 % Change 2026 2025 % Change
---------- -------- ------- -------- ------- ------- --------
Net revenue 27,040 37,389 -27.7% 88,704 107,544 -17.5%
Gross
profit (1,622) 5,008 -132.4% 4,747 23,452 -79.8%
Gross
margin -6.0% 13.4% -19.4 pp 5.4% 21.8% -16.5 pp
Operating
income
(loss) (64,693) (10,882) -494.5% (80,836) (20,186) -300.5%
Adjusted
operating
income
(loss) (11,391) (10,220) -11.5% (27,303) (16,258) -67.9%
-- Our Cannabis Operations results remain below our expectations, and we are
moving aggressively to reshape the segment into a more focused and
efficient business. Most of the revenue decline in the third quarter was
attributable to our exit from the unprofitable domestic dried flower
category and our increased focus on higher-value products.
-- Profitability was impacted by a $52 million non-cash goodwill impairment
reflecting current business trends, as well as $6 million in other
impacts, mostly driven by inventory adjustments related to the exit from
the dried flower category and Jeeter cost variances. During the third
quarter, we took decisive actions to reduce manufacturing costs and other
operating expenses, particularly at our Kelowna manufacturing facility,
including a reduction of more than 30% of the workforce at the site. The
P&L benefits of these cost reductions are expected to begin contributing
to results in the fourth quarter.
Investments
-- As of September 30, 2026, the Company's portfolio of cannabis-related
investments had a carrying value of $485.2 million, including $467.7
million to SunStream Bancorp Inc. ("SunStream"). This carrying value was
increased by $70.0 million during the third quarter of 2026, primarily
driven by additional contributions to fund the buildout of the
Gainesville, Florida cultivation facility, SNDL's participation in
Parallel's rights offering, and the purchase of an incremental portion of
Parallel's debt.
-- On July 27, 2026, the restructuring of Parallel was completed, providing
SNDL with indirect majority economic exposure to the company. During the
third quarter, SNDL participated in a Parallel rights offering, while
other minority holders declined to participate, increasing SNDL's
indirect equity interest from approximately 67% to approximately 92%.
SNDL continues to evaluate a pathway to directly own and consolidate
Parallel's U.S. medical cannabis operations while maintaining compliance
with the applicable Nasdaq requirements. Consistent with recent
public-market precedents, SNDL is evaluating structures that distinguish
medical cannabis operations from adult-use exposure, with the latter
expected to remain outside SNDL's consolidated operations. The Company is
actively advancing this work and expects to provide further clarity as
the structure and timing are finalized, subject to applicable legal,
regulatory, accounting and Nasdaq requirements.
-- Following the completion of Parallel's restructuring, SNDL also financed
SunStream's purchase of an additional portion of Parallel's takeback debt
at 75% of face value, increasing SunStream's debt ownership from 39.4% to
69.4%.
-- The Investments segment generated $7.9 million of operating income during
the third quarter of 2026, including $6.9 million from SNDL's share of
profit from SunStream's equity-accounted investees, primarily reflecting
an increase in the valuation of Parallel.
-- The previously disclosed restructuring process relating to Skymint
continues. On April 1, 2026, the Michigan Supreme Court agreed to hear
oral argument on applications for leave to appeal. The Court has not
reached a decision on the merits. Timing and outcomes remain uncertain
and are subject to court process and other factors.
-- On April 23, 2026, the United States Department of Justice and the United
States Drug Enforcement Administration issued an order placing Food and
Drug Administration-approved cannabis products and qualifying
state-regulated medical cannabis in Schedule III of the United States
Controlled Substances Act, while initiating an expedited administrative
process to consider the broader rescheduling of cannabis, including
adult-use cannabis, from Schedule I to Schedule III. The administrative
hearing concluded in July 2026, with a final determination on broader
rescheduling still pending.
Equity Position
-- $617.8 million of unrestricted cash, marketable securities and
investments, including investments in equity-accounted investees, and no
outstanding debt at September 30, 2026, resulting in a net book value of
$1.0 billion.
-- During the third quarter of 2026, the Company purchased for cancellation
5,431,300 common shares at a weighted average price, excluding
commissions, of US$1.31 per share. Year-to-date through October 22, 2026,
the Company had purchased for cancellation 23,088,153 common shares,
resulting in 243,320,644 common shares outstanding.
-- As recently communicated, the Company's Board of Directors has directed
management to pursue a possible substantial issuer bid ("SIB") for an
aggregate purchase price of up to C$50 million and at a price per share
not exceeding C$1.92 (US$1.35). If completed and fully subscribed at the
maximum price, the SIB could reduce the Company's common shares
outstanding by more than an additional 10%. SNDL will continue to
evaluate opportunities to repurchase shares where management believes
doing so is in the best interests of SNDL and its shareholders. In this
context, and subject to approval by SNDL's Board of Directors, we expect
to proceed with the renewal of the share repurchase program upon its
expiration on November 20, 2026, supported by continued free cash flow
and potential targeted asset sales, including non-core real estate and
other operating assets.
This press release is intended to be read in conjunction with the Company's condensed consolidated interim financial statements and the notes thereto for the three and nine months ended September 30, 2026, and the accompanying Management's Discussion and Analysis. These documents are available under the Company's profile on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov/edgar.shtml.
CONFERENCE CALL
The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Tuesday, October 27, 2026.
WEBCAST ACCESS
To access the live webcast of the call, please visit the following link:
https://edge.media-server.com/mmc/p/wcotys5n
REPLAY
A replay of the webcast will be available at https://sndl.com/financials/quarterly-results/default.aspx
ABOUT SNDL INC.
SNDL Inc. (NASDAQ: SNDL, CSE: SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis companies and the largest private-sector liquor and cannabis retailer in Canada, with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. With products available in licensed cannabis retail locations nationally, SNDL's consumer-facing cannabis brands include Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Value Buds, Grasslands, Vacay, Pearls by Grön, No Future and Bhang Chocolate. SNDL's investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the North American cannabis industry. For more information, please visit www.sndl.com
For more information:
Tomas Bottger
Investor Relations, SNDL Inc.
O: 1.587.327.2017
E: investors@sndl.com
Forward-Looking Information Cautionary Statement
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"), including, but not limited to, statements regarding the Company's operational goals, plans and key priorities, the strategic review of the Cannabis Operations segment, including its scope, potential alternatives and outcomes, and the expected benefits of any actions resulting from the review, the Company's ability to deploy capital and the expected benefits thereof, expectations related to the Jeeter contract, the growth opportunities available to SNDL and the expected benefits thereof, expectations with respect to the 1CM transaction, including the satisfaction of certain regulatory approvals, the progress of the Sunstream restructurings, expectations with respect to the Skymint and Parallel restructuring processes, the feasibility, structure, timing and expectations related to the Company obtaining direct ownership and control of, and consolidating, qualifying U.S. medical cannabis operations of Parallel, SNDL's corporate restructuring program, including the timing to conclude the restructuring and expected benefits thereof, the expected benefits of the enterprise resource planning ("ERP") system consolidation, SNDL's ability to recover the senior secured notes held in Cannabist, the timing and expected impact of reclassifying cannabis from Schedule I to Schedule III under the United States Controlled Substances Act, the Company's retail strategy, and any other potential forms of shareholder value creation. Forward-looking statements are frequently characterized by words such as "aim", "anticipate", "assume", "believe", "contemplate", "continue", "could", "due", "estimate", "expect", "goal", "intend", "may", "objective", "plan", "predict", "potential", "positioned", "pioneer", "seek", "should", "target", "will", "would", and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the Company's business and the industry in which it operates and management's beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond its control. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Please see "Risk Factors" in the Company's annual information form dated March 11, 2026, and the risk factors included in our other public disclosure documents for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Condensed Consolidated Interim Statement of Loss and
Comprehensive Loss
(Expressed in thousands of Canadian dollars, except
per share amounts)
Three months ended Nine months ended
September 30 September 30
2026 2025 2026 2025
----------------- -------- -------- ------- -------
Net revenue 237,994 244,219 669,666 693,902
Cost of sales 180,108 180,042 502,619 505,483
------------------- ------- -------- ------- -------
Gross profit 57,886 64,177 167,047 188,419
Investment income 927 1,777 3,472 6,162
Share of profit
(loss) of
equity-accounted
investees 6,934 (234) 5,084 (4,387)
General and
administrative 43,284 45,967 132,732 137,702
Sales and marketing 3,462 3,617 11,136 10,768
Depreciation and
amortization 12,659 12,928 38,145 39,076
Share-based
compensation 1,767 10,883 5,033 15,190
Restructuring costs 577 1,134 1,608 2,287
Asset impairment,
net 52,331 2,051 52,151 2,971
Other income -- -- (81) --
Research and
development -- 156 12 354
(Gain) loss on
disposition of
assets (16) 34 139 (54)
------------------- ------- -------- ------- -------
Operating loss (48,317) (11,050) (65,272) (18,100)
Other expenses, net (2,464) (2,269) (6,424) (7,041)
------------------- ------- -------- ------- -------
Loss before income
tax (50,781) (13,319) (71,696) (25,141)
Income tax
(expense)
recovery (8) -- 3,174 --
------------------- ------- -------- ------- -------
Net loss (50,789) (13,319) (68,522) (25,141)
Equity-accounted
investees - share
of other
comprehensive
(loss) income (29) 7,709 10,625 (13,250)
Investments at fair
value through
other
comprehensive
income ("FVOCI") -
change in fair
value 2,773 12,940 1,690 9,754
------------------- ------- -------- ------- -------
Comprehensive
(loss) income (48,045) 7,330 (56,207) (28,637)
Condensed Consolidated Interim Statement of Financial
Position
(Expressed in thousands of Canadian dollars)
As at September 30, 2026 December 31, 2025
---------------------------- ------------------- -----------------
Assets
Current assets
Cash and cash equivalents 132,479 252,243
Restricted cash 8,162 20,081
Marketable securities 139 84
Accounts receivable 31,734 27,643
Biological assets 2,407 3,120
Inventory 128,721 126,877
Prepaid expenses and
deposits 16,614 15,566
Investments 106 484
Assets held for sale 700 746
Net investment in
subleases 2,997 2,775
----------------------------- ------------------ -----------------
324,059 449,619
Non-current assets
Long-term deposits and
receivables 2,457 4,526
Right of use assets 131,608 138,353
Property, plant and
equipment 139,376 151,900
Net investment in
subleases 9,954 11,643
Intangible assets 56,434 58,520
Investments 17,314 11,574
Equity-accounted investees 467,730 385,534
Goodwill 75,238 124,248
----------------------------- ------------------ -----------------
Total assets 1,224,170 1,335,917
----------------------------- ------------------ -----------------
Liabilities
Current liabilities
Accounts payable and
accrued liabilities 46,902 56,747
Lease liabilities 35,706 35,462
82,608 92,209
Non-current liabilities
Lease liabilities 126,614 134,471
Other liabilities 7,753 8,041
----------------------------- ------------------ -----------------
Total liabilities 216,975 234,721
----------------------------- ------------------ -----------------
Shareholders' equity
Share capital 2,127,355 2,310,398
Warrants 306 306
Contributed surplus 53,377 54,038
Accumulated deficit (1,225,053) (1,302,441)
Accumulated other
comprehensive income
("AOCI") 51,210 38,895
----------------------------- ------------------ -----------------
Total shareholders' equity 1,007,195 1,101,196
----------------------------- ------------------ -----------------
Total liabilities and
shareholders' equity 1,224,170 1,335,917
----------------------------- ------------------ -----------------
Condensed Consolidated Interim Statement of Cash Flows
(Expressed in thousands of Canadian dollars)
Three months ended Nine months ended
September 30 September 30
2026 2025 2026 2025
---------------------- -------- -------- -------- -------
Cash provided by (used
in):
Operating activities
Net loss for the
period (50,789) (13,319) (68,522) (25,141)
Adjustments for:
Income tax expense
(recovery) 8 -- (3,174) --
Interest and fee
income (927) (1,675) (3,417) (5,849)
Change in fair
value of
biological assets 585 180 594 (2,559)
Change in fair
value of inventory
sold (276) 349 249 1,313
Share-based
compensation 1,767 10,883 5,033 15,190
Depreciation and
amortization 13,893 13,972 41,998 42,108
(Gain) loss on
disposition of
assets (16) 34 139 (54)
Inventory
impairment and
obsolescence 3,455 1,833 6,057 2,663
Finance costs, net 1,951 1,812 6,007 5,149
Change in estimate
of fair value of
derivative
warrants -- (1) -- (26)
Unrealized foreign
exchange loss
(gain) 180 (153) (832) 40
Transaction costs -- -- 10 --
Asset impairment,
net 52,331 2,051 52,151 2,971
Share of (profit)
loss of
equity-accounted
investees (6,934) 234 (5,084) 4,387
Unrealized (gain)
on marketable
securities -- (102) (55) (313)
Additions to
marketable
securities -- -- 151 313
Income distributions
from
equity-accounted
investees 315 -- 315 68
Interest received 822 1,409 3,377 5,628
Exercise of
cash-settled
deferred share
units -- -- (474) --
Change in non-cash
working capital 2,185 14,194 (8,805) (282)
------------------------ ------- -------- -------- -------
Net cash provided by
operating activities 18,550 31,701 25,718 45,606
------------------------ ------- -------- -------- -------
Investing activities
Additions to
property, plant and
equipment (1,196) (5,185) (5,620) (8,853)
Additions to
investments -- -- (4,183) (16,414)
Principal payments
from investments 121 129 359 27,293
Proceeds from
disposal of
investments -- 15,058 -- 15,058
Capital
(contributions)
distributions from
equity-accounted
investees (60,762) 481 (63,628) 4,273
Proceeds from
disposal of
property, plant and
equipment 538 -- 2,332 166
Acquisitions -- -- (2,900) (1,000)
Change in non-cash
working capital 75 39 712 10
------------------------ ------- -------- -------- -------
Net cash (used in)
provided by investing
activities (61,224) 10,522 (72,928) 20,533
------------------------ ------- -------- -------- -------
Financing activities
Change in restricted
cash 11,950 -- 11,950 --
Payments on lease
liabilities, net (10,228) (9,920) (30,385) (29,217)
Repurchase of common
shares (10,042) (3) (43,113) (15,034)
Change in non-cash
working capital 265 57 1,136 334
------------------------ ------- -------- -------- -------
Net cash used in
financing activities (8,055) (9,866) (60,412) (43,917)
------------------------ ------- -------- -------- -------
Change in cash and cash
equivalents (50,729) 32,357 (107,622) 22,222
Adjustment on initial
application of
amendments to IFRS 9 on
January 1, 2026 -- -- (12,142) --
Cash and cash
equivalents, beginning
of period 183,208 208,224 252,243 218,359
------------------------ ------- -------- -------- -------
Cash and cash
equivalents, end of
period 132,479 240,581 132,479 240,581
------------------------ ------- -------- -------- -------
NON-IFRS MEASURES
Certain specified financial measures in this news release are non-IFRS measures. These terms are not defined by IFRS and, therefore, may not be comparable to similar measures reported by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for or superior to measures of performance prepared in accordance with IFRS. These measures are presented and described in order to provide shareholders and potential investors with additional measures in understanding the Company's operating results in the same manner as the management team.
ADJUSTED OPERATING INCOME (LOSS)
Adjusted operating income (loss) is a non-IFRS financial measure which the Company uses to evaluate its operating performance in a similar manner to its management team. The Company defines adjusted operating income (loss) as operating income (loss) less restructuring costs (recovery), goodwill and intangible asset impairments and asset impairments triggered by restructuring activities.
The following tables reconcile adjusted to un-adjusted operating income (loss) for the periods noted.
Cannabis Cannabis Cannabis Liquor
($000s) Retail Operations Total Retail Investments Corporate Total
----------------- --------- ---------- -------- ------ ----------- --------- -------
Three months ended September 30, 2026
----------------------------------------------------------------------------------------------
Operating income
(loss) 5,244 (64,693) (59,449) 6,035 7,861 (2,764) (48,317)
Adjustments:
Restructuring
costs 40 313 353 2 -- 222 577
Goodwill and
intangible
asset
impairments -- 52,022 52,022 -- -- -- 52,022
Impairments
triggered by
restructuring -- 967 967 -- -- -- 967
------------------ -------- ---------- -------- ------ ----------- --------- -------
Adjusted operating
income (loss) 5,284 (11,391) (6,107) 6,037 7,861 (2,542) 5,249
------------------ -------- ---------- -------- ------ ----------- --------- -------
Cannabis Cannabis Cannabis Liquor
($000s) Retail Operations Total Retail Investments Corporate Total
----------------- --------- ---------- -------- ------ ----------- --------- -------
Nine months ended September 30, 2026
----------------------------------------------------------------------------------------------
Operating income
(loss) 9,328 (80,836) (71,508) 5,899 8,340 (8,003) (65,272)
Adjustments:
Restructuring
costs 75 544 619 227 -- 762 1,608
Goodwill and
intangible
asset
impairments -- 52,022 52,022 -- -- -- 52,022
Impairments
triggered by
restructuring -- 967 967 -- -- -- 967
------------------ -------- ---------- -------- ------ ----------- --------- -------
Adjusted operating
income (loss) 9,403 (27,303) (17,900) 6,126 8,340 (7,241) (10,675)
------------------ -------- ---------- -------- ------ ----------- --------- -------
Cannabis Cannabis Cannabis Liquor
($000s) Retail Operations Total Retail Investments Corporate Total
----------------- --------- ---------- -------- ------ ----------- --------- -------
Three months ended September 30, 2025
----------------------------------------------------------------------------------------------
Operating income
(loss)(1) 5,047 (10,882) (5,835) 6,591 1,543 (13,349) (11,050)
Adjustments:
Restructuring
costs -- 258 258 -- -- 876 1,134
Impairments
triggered by
restructuring -- 404 404 -- -- -- 404
------------------ -------- ---------- -------- ------ ----------- --------- -------
Adjusted operating
income (loss) 5,047 (10,220) (5,173) 6,591 1,543 (12,473) (9,512)
------------------ -------- ---------- -------- ------ ----------- --------- -------
Cannabis Cannabis Cannabis Liquor
($000s) Retail Operations Total Retail Investments Corporate Total
----------------- --------- ---------- -------- ------ ----------- --------- -------
Nine months ended September 30, 2025
----------------------------------------------------------------------------------------------
Operating income
(loss)(1) 10,557 (20,186) (9,629) 10,884 1,775 (21,130) (18,100)
Adjustments:
Restructuring
costs -- 828 828 -- -- 1,459 2,287
Impairments
triggered by
restructuring -- 3,100 3,100 -- -- -- 3,100
------------------ -------- ---------- -------- ------ ----------- --------- -------
Adjusted operating
income (loss) 10,557 (16,258) (5,701) 10,884 1,775 (19,671) (12,713)
------------------ -------- ---------- -------- ------ ----------- --------- -------
(4) In 2026, the Company began allocating applicable direct and indirect overhead costs from the corporate segment to each individual operating segment all categorized within general and administrative expenses. The Company has recast the comparative period to illustrate the impact of these allocations had they been done during the prior period.
GROSS MARGIN
Gross margin is a supplementary financial measure calculated as gross profit divided by net revenue for the periods presented. This measure evaluates the underlying profitability of our operations and provides useful information about the Company's ability to price products effectively, manage input costs, drive operating efficiencies, and compare results across periods and business segments
FREE CASH FLOW
Free cash flow is a non-IFRS financial measure which the Company uses to evaluate its financial performance, providing information which management believes to be useful in understanding and evaluating the Company's ability to generate positive cash flows as it removes cash used for non-operational items. The Company defines free cash flow as the total change in cash and cash equivalents less cash used for common share repurchases, dividends (if any), changes to debt instruments, changes to long-term investments, net cash used for acquisitions plus cash provided by dispositions (if any).
The following table reconciles free cash flow to change in cash and cash equivalents for the periods noted.
Three months ended Nine months ended
September 30 September 30
($000s) 2026 2025 2026 2025
----------------- -------- -------- -------- -------
Change in cash and
cash equivalents (50,729) 32,357 (107,622) 22,222
Adjustments:
Repurchase of
common shares 10,042 3 43,113 15,034
Changes to
long-term
investments 60,641 (15,668) 67,301 (30,523)
Acquisitions,
net of cash
acquired -- -- 2,900 1,000
------------------- ------- -------- -------- -------
Free cash flow 19,954 16,692 5,692 7,733
------------------- ------- -------- -------- -------
SAME-STORE SALES
Same-store sales is a non-IFRS financial measure which the Company uses to evaluate its financial performance in its retail segments. Same store sales provides information which management believes to be useful to investors, analysts and others in understanding and evaluating the Company's sales trends excluding the effect of the opening and closure of stores.
Same store sales refers to the revenue generated by the Company's existing retail locations during the current and prior comparison periods.
ADJUSTED EBITDA
Adjusted EBITDA is a non-IFRS financial measure which the Company uses to evaluate its operating performance. Adjusted EBITDA provides information to investors, analysts, and others to aid in understanding and evaluating the Company's operating results. The Company defines adjusted EBITDA as net earnings (loss) before inventory and biological assets fair value and impairment adjustments, share of (gain) loss of equity-accounted investees, depreciation and amortization, share-based compensation expense, restructuring costs, asset impairment, gain or loss on disposal of property, other expenses, net, income tax expense (recovery) and excluding non-recurring items including ERP implementation costs and litigation settlements, net of recoveries.
Three months ended Nine months ended
September 30 September 30
($000s) 2026 2025 2026 2025
-------------------- -------- -------- ------- -------
Net earnings (loss) (50,789) (13,319) (68,522) (25,141)
Adjustments:
Inventory and
biological assets
fair value and
impairment
adjustments 3,764 2,362 6,900 1,417
Share of loss
(profit) of
equity-accounted
investees (6,934) 234 (5,084) 4,387
Depreciation and
amortization 12,659 12,928 38,145 39,076
Share-based
compensation 1,767 10,883 5,033 15,190
Restructuring costs 577 1,134 1,608 2,287
Asset (reversal)
impairment 52,331 2,051 52,151 2,971
Loss (gain) on
disposition of
PP&E (16) 34 139 (54)
Other expenses, net 2,464 2,269 6,424 7,041
Income tax recovery 8 -- (3,174) --
Non-recurring items (15) (501) 549 (696)
---------------------- ------- -------- ------- -------
Adjusted EBITDA 15,816 18,075 34,169 46,478
---------------------- ------- -------- ------- --
Comments